STEPHEN DOUGLAS RUBIN, MD
Osteopathic Medicine at Collegeville Rd, Collegeville, PA
License number
Pennsylvania MD034245E
Category
Osteopathic Medicine
Type
Medical Oncology
Address
Address
2
1250 S Collegeville Rd, Collegeville, PA 19426
14 Bridle Path, Southampton, NJ 08088
14 Bridle Path, Southampton, NJ 08088
Phone
(484) 620-9545
Professional information
Dr. Stephen D Rubin, Collegeville PA - MD (Doctor of Medicine)
Specialties:
Hematology, Medical Oncology, Oncology
Address:
1250 S Collegeville Rd, Collegeville 19426
Certifications:
Hematology, 1999, Internal Medicine, 1992, Medical Oncology, 2012
Awards:
Healthgrades Honor Roll
Languages:
English
Education:
Medical School
Upstate Medical University/ College of Health Professions
Graduated: 1983
Upstate Medical University/ College of Health Professions
Graduated: 1983
Composition Comprising A Combination Of An Aromatase Inhibitor, A Progestin And An Oestrogen And Its Use For The Treatment Of Endometriosis
US Patent:
2011000, Jan 13, 2011
Filed:
Sep 20, 2010
Appl. No.:
12/886269
Inventors:
Stephen Rubin - Southampton NJ, US
Assignee:
ASTRAZENECA AB - Sodertalje
International Classification:
A61K 31/56, A61K 31/5685, A61P 35/00, A61K 31/57, A61K 31/566
US Classification:
514170
Abstract:
The invention relates to a method of treating endometriosis using a combination of an aromatase inhibitor, a progestin and an oestrogen. The invention also relates to pharmaceutical formulations comprising said combination.
Cancer Treatment Method
US Patent:
2008030, Dec 11, 2008
Filed:
Dec 16, 2005
Appl. No.:
11/721675
Inventors:
Stephen Rubin - Collegeville PA, US
Assignee:
SMITHKLINE BEECHAM (CORK) LIMITED - County Cork
International Classification:
A61K 31/517, A61P 35/00
US Classification:
51426624
Abstract:
Disclosed herein is a method of treating breast cancer that has metastasized to the brain in a mammal by administration of 4-quinazolinamines and pharmaceutical compositions containing the same. In particular, the method relates to methods of treating breast cancer brain metastases which overexpress erbB2 by administration of N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methanesulphonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine and salts and solvates thereof.
Composition Comprising A Combination Of An Aromatase Inhibitor, A Progestin And An Oestrogen And Its Use For The Treatment Of Endometriosis
US Patent:
7910570, Mar 22, 2011
Filed:
Feb 3, 2004
Appl. No.:
10/543584
Inventors:
Stephen Rubin - Southampton NJ, US
Serdar E. Bulun - Chicago IL, US
Serdar E. Bulun - Chicago IL, US
Assignee:
AstraZeneca AB - Sodertalje
International Classification:
A01N 45/00, A61K 31/56
US Classification:
514170, 514171, 514178, 514182, 514899
Abstract:
The invention relates to a method of treating endometriosis using a combination of an aromatase inhibitor, a progestin and an oestrogen. The invention also relates to pharmaceutical formulations comprising said combination.